Porcine Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The porcine vaccines market size is projected to be USD 2.47 billion in 2025, USD 2.78 billion in 2026, and reach USD 4.73 billion by 2031, growing at a CAGR of 11.21% from 2026 to 2031. This report Segments the Industry Into by Target Disease (Porcine Reproductive & Respiratory Syndrome, and More), Technology Platform (Live-Attenuated, and More), Product Formulation (Monovalent Vaccines, and More), Administration Route (Intramuscular, and More), Distribution Channel (Veterinary Hospitals, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Porcine Vaccines Market Trends and Insights

Rising Demand for Pork Protein in Emerging Economies

Rapid urbanization increased Southeast Asian per-capita pork consumption by 7% between 2024 and 2025, making vaccination a prerequisite for contract farming agreements with modern processors. China’s sow herd recovered to 43.9 million head by late 2025, and provincial regulations now require quarterly vaccination logs to be submitted before slaughterhouse entry. Middle-Eastern importers mandate proof of PRRS and influenza immunization on veterinary certificates, even in exporting nations with historically low coverage. Producers view a USD 2-3 per-head vaccine outlay as negligible compared to the financial shock of a 10% mortality event, especially where pork accounts for 40% of animal protein spending. Consequently, the porcine vaccine market is tracking closely with income growth in Vietnam, the Philippines, and southern China.

Increasing Prevalence of PRRS, PEDV & ASF

ASF detections in Philippine herds surged 34% in 2025, forcing culling radii to widen and catalyzing demand for experimental subunit candidates. PRRS still costs U.S. producers USD 664 million annually, and heterologous strains cut performance 5-8% even in vaccinated herds. PRRS recombinant variants emerging in central China erode existing vaccine protection, compelling manufacturers to replace seed strains and sustain demand for fast-pivot platforms. Europe’s winter 2024-2025 PEDV outbreaks demonstrated that waning disease pressure reduces compliance, creating pools of susceptible pigs that amplify the subsequent incursion. These evolutionary dynamics keep the porcine vaccine market on a perpetual R&D cycle, rewarding technologies that enable rapid antigen substitution.

Cold-Chain Logistics Cost in Developing Regions

Keeping vaccines at 2-8 °C adds USD 0.80-1.20 per dose where electricity exceeds USD 0.25/kWh and last-mile transport relies on motorcycles. Surveys in Nigeria, Tanzania, and Uganda revealed that 42% of deliveries exceeded temperature limits, reducing potency by up to 60% and eroding trust in vaccines. Solar refrigerators reduced spoilage in India’s Assam state from 28% to 9%, yet a unit cost of USD 1,500 is prohibitive without a subsidy. The result is cyclical under-vaccination, which perpetuates disease and dampens near-term growth in the porcine vaccine market.

Other drivers and restraints analyzed in the detailed report include:

• Government-Backed Mass-Vaccination Programs
• Shift to Antibiotic-Free Pork Production
• Adverse Reactions & Vaccine Failure with Live-Attenuated Strains

Segment Analysis

Diarrheal formulations held a commanding 27.48% share in 2025, making them the single most significant slice of the porcine vaccine market revenue. Swine influenza lines, however, are advancing at a 12.76% CAGR as H1N1 and H3N2 variants circulate more aggressively in densely stocked barns. Influenza also poses a zoonotic spillover risk, underscoring the need for regulatory agencies to support the rapid development and update of vaccines. PRRS vaccines, long considered indispensable, face efficacy challenges as recombinant field strains evade existing immunogens, necessitating sustained research and development (R&D) investment. ASF remains a white-space opportunity; no globally commercialized dose exists outside of China and Vietnam, but subunit candidates in late-stage development could unlock substantial incremental demand for the porcine vaccine market once regulatory hurdles are cleared.

The performance of diarrheal products is influenced by acute mortality in farrowing units; mortality exceeding 40% in outbreaks justifies immediate allocation of an immunization budget. In contrast, respiratory vaccines appeal to integrators for improving feed efficiency and days-to-market. Both segments illustrate a bifurcation: enteric lines drive steady volume, while respiratory solutions contribute significantly to the growth of the porcine vaccine market.

Live-attenuated formats still accounted for 35.62% of 2025 revenue due to their low cost and durable immunity, yet they shoulder pharmacovigilance burdens and potential reversion events. Recombinant-vector platforms are rising at 14.73% CAGR, benefiting from dual humoral-cellular responses and the absence of live-virus risk. Inactivated vaccines dominate where safety trumps potency, especially for swine influenza, though booster-dose labor can deter smaller producers. Subunit offerings, such as the latest PCV2d constructs, bypass cold-chain fragility, securing uptake in high-temperature regions. DNA and nanoparticle-adjuvanted prototypes in Phase III U.S. trials signal the next frontier, positioning the porcine vaccine market for even faster antigen-switch cycles as pathogen landscapes shift.

Economics influence platform choice: while recombinant doses cost 2-3 times more than MLV products, their predictable safety profile justifies the premium where export certification or consumer labeling is a consideration. Consequently, multinationals deploy tiered portfolios, pricing traditional formats aggressively to defend share while upselling novel vectors to customers with tighter biosecurity requirements.

Complete Report Scope:

• By Disease Type
  • Porcine Reproductive & Respiratory Syndrome
  • Porcine Circovirus Associated Disease
  • Diarrheal Diseases
  • Swine Influenza
  • Classical & African Swine Fever
  • Other Diseases
• By Technology Platform
  • Live-attenuated
  • Inactivated/Killed
  • Toxoid & Subunit
  • Recombinant Vector
  • Other Technology Platform
• By Product Formulation
  • Monovalent Vaccines
  • Multivalent / Combination
• By Administration Route
  • Intramuscular
  • Intradermal
  • Oral & Intranasal Mucosal
• By Distribution Channel
  • Veterinary Hospitals
  • Veterinary Clinics
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 38.35% of 2025 revenue, anchored by the United States’ 74 million-head inventory and export-oriented, vertically integrated systems. Canada’s shift toward antibiotic-free production aligns with U.S. processor mandates, pushing PRRS and PCV sales into double-digit growth during 2024-2025. Mexico’s 6% increase in pork output in 2025 reflects near-shored processing; however, vaccine penetration remains below 50% among smallholders due to credit constraints. The FDA's antimicrobial curbs, effective 2024, will convert vaccines into the default disease-prevention tool, while Zoetis’ USD 120 million investment in a Michigan biologics plant will expand regional capacity by 30% by 2027.

The Asia-Pacific region is projected to grow at a rate of 14.25% annually, driven by China’s post-ASF rebound and subsidies in Southeast Asia. Vietnam’s state funding aims for 80% breeding-herd coverage by 2026, while Japan and South Korea maintain near-universal vaccination but flat herd sizes. India’s pilot programs achieved 91% coverage in participating villages during 2025, hinting at latent potential if logistical hurdles are solved. Australia, disease-free but small in scale, provides a steady niche for erysipelas and leptospirosis doses. Sustained progress hinges on China avoiding major ASF relapses and governments continuing to treat vaccination as a strategic, partially subsidized input.

Europe maintains robust demand due to regulatory enforcement under the Animal Health Law, which classifies PRRS and ASF in the top two disease categories. Germany, Spain, and Denmark generate 58% of the regional pork supply and display near-total vaccine adoption, while Poland and Romania record high double-digit growth due to ongoing ASF incursions in wild boar populations. Spain’s integrated producers increased per-pig vaccine spending to EUR 3.50 in 2025, driven by animal welfare metrics demanded by retailers. The United Kingdom harmonizes with EU standards but seeks quicker pathways for novel platforms, attracting Ceva’s UK-specific Hyogen dossier in 2024. Eastern Europe’s consolidation phase favors multinationals offering technical support tailored to large-scale operations, reinforcing the moderate concentration of the porcine vaccine market.

List of Companies Covered in this Report:

• Biogénesis Bagó
• Bimeda Biologicals
• Boehringer Ingelheim
• Ceva Santé Animale
• Chengdu Tech-Bank/Winsun Bio
• CJ CheilJedang Bio
• Elanco
• Hester Biosciences
• Hipra
• Huvepharma
• IDT Biologika
• Indian Immunologicals
• KM Biologics
• Merck
• Phibro Animal Health
• Qilu Animal Health
• Ringpu Bio-Pharmacy
• Vetoquinol
• Virbac
• Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support